Single-Use Bioreactors Have Become the Default for Biopharmaceutical Manufacturing and Stainless Steel Suites Are Being Retired

The Vessel That Changed Manufacturing Without Changing the Biology

Bioreactors, the vessels in which living cells are cultivated under controlled temperature, pH, dissolved oxygen, and agitation conditions to produce the recombinant proteins, monoclonal antibodies, vaccines, and cell therapies that biopharmaceuticals require, have historically been constructed from stainless steel whose durability, cleanability, and regulatory acceptance created the manufacturing infrastructure that the biopharmaceutical industry built its production facilities around from the 1980s through the 2000s. The stainless steel bioreactor's operational model requires the extensive cleaning in place and sterilisation in place procedures between production batches whose validation, execution, and documentation consume a significant proportion of the facility's operational time and cost and whose failure creates the contamination events that halt production and destroy the batch value that biopharmaceutical manufacturing economics depend on. Single-use bioreactors replace the stainless steel vessel with a sterile, pre-validated, gamma-irradiated plastic biocontainer whose liner is used for a single production run and then discarded, eliminating the CIP and SIP procedures entirely and reducing the between-batch turnaround time from days to hours. The elimination of the CIP validation requirement, the reduction in water for injection consumption, and the elimination of cleaning chemical costs create the operational advantages that single-use bioreactors provide above and beyond the capital cost advantage of a manufacturing facility whose bioreactor capacity is provided by disposable equipment rather than the permanent stainless steel infrastructure whose installation and validation represent a multi-year capital commitment.

The single-use bioreactor market, valued at approximately $6.8 billion in 2026 and growing at over fourteen percent annually toward $14.2 billion by 2032, has achieved the dominant position in new biopharmaceutical manufacturing capacity installation for upstream cell culture production in the working volume range from one litre to two thousand litres, with only the largest commercial production bioreactors above approximately ten thousand litres remaining in the domain where stainless steel's lower per-litre capital cost and unlimited operational life maintain the economic advantage over single-use alternatives. The cell and gene therapy manufacturing sector, whose autologous manufacturing processes requiring patient-specific, single-batch production are architecturally unsuitable for the stainless steel facility model whose shared infrastructure and multi-batch production economics require the scale of output that personalised cell therapy cannot provide, has been the fastest-growing single-use bioreactor application whose adoption of single-use manufacturing as the only practical production model has created the demand growth that bioreactor suppliers are serving through product development specifically targeted at cell therapy upstream cultivation requirements.

Cytiva and the Platform Approach

Cytiva, the life science tools company whose Xcellerex XDR single-use stirred tank bioreactor platform established the large-scale single-use bioreactor standard for monoclonal antibody manufacturing, has built the market leadership position in single-use upstream cell culture through the combination of its Xcellerex hardware and its ReadyToProcess consumable supply chain whose integration of matched biocontainers, cell culture media, filters, and chromatography consumables creates the turnkey manufacturing system that biopharmaceutical contract manufacturers and integrated pharmaceutical producers adopt as complete single-use manufacturing infrastructure rather than individual equipment purchases. Its Xcellerex XDR-500 and XDR-2000 systems, whose five hundred litre and two thousand litre working volumes serve the commercial-scale monoclonal antibody production that the single-use format's upper practical scale limit encompasses, are deployed at multiple major contract development and manufacturing organisations including Lonza, Samsung Biologics, and Fujifilm Diosynth Biotechnologies whose commercial mAb manufacturing facilities are built around the single-use upstream culture equipment that Cytiva supplies. Sartorius, the German laboratory and bioprocess equipment company whose Biostat STR single-use stirred tank bioreactor competes directly with Cytiva's Xcellerex for the commercial mAb manufacturing scale, has established its competing position through the Biostat STR's cell culture performance data and its integration with Sartorius's ambr microscale bioreactor development system whose process scale-up pathway from fifteen millilitre ambr development to two hundred and fifty litre Biostat STR production uses consistent process parameters whose transferability reduces the scale-up development time that biopharmaceutical process development requires.

Thermo Fisher Scientific's HyPerforma single-use bioreactor platform, which serves the mid-scale upstream manufacturing market whose working volumes from fifty to two thousand litres span the clinical to early commercial production stages, competes with both Cytiva and Sartorius through the Thermo Fisher group's integrated supply chain that encompasses cell culture media, upstream equipment, harvest clarification, and purification consumables from a single supplier whose procurement relationship and technical support infrastructure large pharmaceutical manufacturers and CDMOs value as supply chain simplification. Merck's Mobius single-use bioreactor product range, integrated with MilliporeSigma's bioprocess consumable portfolio, provides the single-use bioreactor option for the segment of biopharmaceutical manufacturers whose existing Merck bioprocess supply relationships make the Mobius the natural procurement choice within a single-supplier bioprocess strategy whose integration of upstream, downstream, and formulation single-use equipment creates the manufacturing facility without a single stainless steel vessel.

The Cell and Gene Therapy Manufacturing Application

The cell and gene therapy manufacturing application represents the single-use bioreactor market's highest-growth segment whose unique requirements, including the small batch sizes of autologous cell therapy whose per-patient production volumes are measured in litres rather than the hundreds of litres of commercial mAb campaigns, the high biological activity requirements of viral vector production whose process sensitivity to contamination makes single-use's elimination of CIP risk particularly valuable, and the rapid scale-up requirements of cell therapy companies whose clinical to commercial production transitions must be completed faster than conventional biologics to serve patient populations whose disease severity creates the urgency that single-use's shorter facility build and validation timeline serves, are creating the bespoke single-use bioreactor product development that Cytiva, Sartorius, Pall Biotech, and PBS Biotech are pursuing as the cell therapy manufacturing market's capital investment accelerates.

Top 10 Companies in Single-Use Bioreactors and Bioprocess Equipment Globally

1. Cytiva (Xcellerex XDR): US life science company with Xcellerex XDR stirred tank bioreactor as the commercial mAb manufacturing single-use standard; its ReadyToProcess integrated consumable supply chain and its deployment at Lonza, Samsung Biologics, and Fujifilm Diosynth create the single-use bioreactor market leader whose platform adoption defines the large-scale single-use upstream manufacturing benchmark.
2. Sartorius (Biostat STR): German bioprocess equipment company with Biostat STR competing at commercial mAb scale and ambr scale-up pathway; its process parameter transferability from ambr development to STR production and its cell culture performance data create the competing single-use bioreactor platform whose ambr-to-STR development workflow is the most commercially differentiated process development feature.
3. Thermo Fisher Scientific (HyPerforma): US life science company with HyPerforma single-use bioreactor platform integrated with cell culture media and downstream consumables; its integrated supply chain from media to purification and its clinical to commercial scale range create the single-use bioreactor supplier whose integration with Thermo Fisher's complete bioprocess portfolio creates the broadest single-supplier single-use manufacturing system.
4. Merck (Mobius): German science and technology company with Mobius single-use bioreactor integrated with MilliporeSigma bioprocess consumables; its single-supplier bioprocess strategy from upstream to formulation and its pharmaceutical manufacturer customer relationships create the single-use bioreactor option for the Merck bioprocess supply chain whose integration creates procurement simplification for large pharmaceutical manufacturers.
5. Pall Biotech (Danaher): US filtration and bioprocess company with iCELLis fixed-bed bioreactor for viral vector and cell therapy manufacturing; its packed bed bioreactor technology for anchorage-dependent cell culture and its viral vector production references create the single-use bioreactor specialist for the cell and gene therapy manufacturing application where fixed-bed technology provides higher cell density and productivity than stirred tank formats.
6. PBS Biotech: US bioreactor company with Vertical-Wheel single-use bioreactor for gentle cell culture agitation; its low-shear agitation and its stem cell and cell therapy manufacturing references create the single-use bioreactor whose mechanical design addresses the shear sensitivity of human cells in cell therapy applications where the conventional stirred tank impeller creates cell damage that reduces product quality and patient safety.
7. Finesse Solutions (Thermo Fisher): US bioprocess control company with single-use bioreactor control systems; its SmartSystem single-use control platform and its process analytical technology integration create the control system company whose measurement and control capability enables the single-use bioreactor to meet the process control requirements that Good Manufacturing Practice regulations specify for commercial biopharmaceutical production.
8. CelCradle (TAP Biosystems): UK single-use bioreactor company with rocking motion bioreactor for viral vector and cell therapy manufacturing; its oscillating tray design and its adherent cell culture capability create the alternative single-use bioreactor technology for the cell and gene therapy manufacturing application where anchorage-dependent cell growth requires the surface area that rocking bioreactor designs provide within a single-use format.
9. Eppendorf: German laboratory equipment company with BioBLU single-use bioreactor for process development scale; its BioBLU stirred single-use vessel and its DASbox mini bioreactor system create the single-use bioreactor supplier for the research and process development scale where Eppendorf's laboratory equipment heritage and customer relationships provide the commercial entry point into biopharmaceutical customers' single-use procurement.
10. Kuhner: Swiss bioprocess equipment company with shaken bioreactor systems for seed train and process development; its ShakerXL and orbital shaker bioreactor systems and its Swiss bioprocess engineering heritage create the shaken bioreactor specialist whose orbital agitation technology provides the alternative to stirred tank mixing for the upstream seed train steps whose smaller volume and simpler scale-up requirements suit shaken system agitation.